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Prior exposure to poison ivy and poison oak, which are plants in the Anacardiacea family and contain 
high levels of urushiol, appear to be a risk factor for delayed hypersensitivity reactions to mango fruits. 
Cross-sensitization between these plants and mangos is believed to be secondary to an overlap in 
the urushiol antigen and 5-resorcinol, found predominately in mango peels. This unique combination 
of sensitization and reaction constitutes a type IV hypersensitivity response, mediated and driven by T 
cells reacting to similar antigens. We present a case of an otherwise healthy man, with a remote history 
of poison ivy exposure, who presented with a delayed but significant reaction to mango fruit. Obtaining 
the patient’s history of prior plant exposures and reactions was key to isolating the likely underlying 
causation of his presentation. [Clin Pract Cases Emerg Med. 2019;3(3):361–363.]
INTRODUCTION
Urushiol is an allergenic substance found in the 
Anacardiaceae family, most commonly known for poison ivy 
(Toxicodendron radicans) and poison oak (T. diversilobum).1 
Presentations of patients who come in direct contact to urushiol-
containing plants include pruritus, erythema, vesicles, bullae, 
and localized edema. While systemic reactions like anaphylaxis 
can cause airway compromise, the burning and inhalation of 
urushiol-containing plants can cause acute airway complications 
such as tracheitis and pulmonary edema.2 Although contact 
dermatitis and airway reactions are well documented in the 
literature, a lesser-known reaction from prior urushiol exposure 
is hypersensitization to mango fruits. We present a case of a 
41-year-old man with suspected mango dermatitis, incited by 
mango handling after remote exposure to poison ivy.
CASE REPORT
An otherwise healthy 41-year-old man presented to the 
emergency department (ED) with a severely worsening, 
four-day-old diffuse, pruritic rash, which began in the 
inguinal regions bilaterally but had since spread to his 
trunk and extremities. The patient’s primary complaint was 
insomnia secondary to his pruritis. He initially denied any 
new medications or other exposures but did endorse a distant 
episode of contact dermatitis to poison ivy two years prior. On 
arrival, his vitals included temperature of 98.3º Fahrenheit, 
blood pressure of 133/87 millimeters of mercury, heart rate of 
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69 beats per minute, respirations of 18 per minute, and a pulse 
oximetry of 100% on room air.  
The patient’s physical exam was remarkable for a 
macular, blanching, non-vesicular, erythematous rash on all 
extremities, chest, and back, sparing the palms, soles, and 
oral mucosa. Lungs were clear to auscultation in all fields. 
Further diet history detailed consumption of two mangos two 
days prior to the onset of the rash. The patient’s wife, who 
accompanied him to the ED, had also consumed mangos 
two days prior but was asymptomatic. Although both the 
patient and his wife handled the mango peels, the wife did not 
endorse prior plant exposures resulting in rash.
Given the patient’s substantial discomfort, intravenous 
(IV) access was established, and 50 milligrams (mg) of 
diphenhydramine and 50 mg ranitidine were parenterally 
administered. This resulted in significant relief of pruritus and 
mild improvement in visible rash. After a brief observation 
period, the patient was discharged home on 60 mg of oral 
prednisone for five days and 20 mg of oral loratadine, as 
needed. Of note, the patient deferred the first steroid dose in 
the ED due to the evening time of presentation and a remote 
history of insomnia after taking steroids. He was contacted 
five days after his ED visit with almost complete resolution of 
symptoms and significant improvement in insomnia with over-
the-counter (OTC) oral diphenhydramine. Extending steroid 
treatment for an additional week was discussed, but the 
patient declined based on the improvement of his symptoms. 
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What do we already know about this clinical entity? 
Urushiol is an allergen of poison ivy and poison 
oak. Prior exposure to it can cause a type 4 
hypersensitivity response upon subsequent handling 
of mango peels. 
What makes this presentation of disease reportable? 
We describe a delayed, nonspecific dermatitis whose 
etiology was discovered only upon obtaining a detailed 
history of prior allergic reactions to poison ivy.
What is the major learning point? 
Patients who previously experienced hypersensitivity 
reactions to poison ivy or poison oak are at risk for 
hypersensitivity reactions when handling mango peels.
How might this improve emergency medicine 
practice? 
When approaching an undifferentiated rash, an 
accurate history of prior reactions and allergies 
can help identify the etiology of the rash.
He was contacted again approximately three months after his 
ED visit and denied any rebound symptoms.
DISCUSSION
The classic hypersensitivity framework of the Gel and 
Coombs system defines four main classes of reactions: types 
I-IV. In brief, type I reactions are mediated by antigens cross-
linking immunoglobulin (Ig) E, causing mast cells and basophils 
to release histamine and other vasoactive contents.3 Type I 
responses range from seasonal allergies to asthma to the extreme 
of anaphylaxis. Type II reactions are predominately mediated 
by IgG and IgM, stimulating phagocytes and natural killer 
cells to either uptake IgG and IgM tagged antigens or active 
complement.3 Examples of type II responses include hemolytic 
anemia and basement membrane disease. Type III reactions are 
also mediated by IgG but cause pathology by the formation of 
immune complexes.3 These complexes deposit around small 
vessels and tissues and can manifest in diseases such as systemic 
lupus erythematosus and glomerulonephritis. Finally, type IV 
reactions are T-cell mediated. After initial sensitization to an 
antigen, T-cells release damaging cytokines upon subsequent 
exposure to structurally similar antigens.4 Unlike types I-III, type 
IV responses do not involve Igs. These responses can manifest 
from contact dermatitis to Stevens-Johnson syndrome.4
Urushiol is a well-known hapten to skin proteins that 
induces a type IV hypersensitivity response.2 After initial 
sensitization to urushiol, typically from contact with poison 
ivy or poison oak, subsequent exposures to urushiol produce 
a cell-mediated memory response after two to three days.2 
Limited studies demonstrated a cross-hypersensitivity response 
between urushiol and the mango compound, 5-resorcinol, 
found predominantly in the skin, leaves, and stems of mango 
fruits.5 5-resorcinol, along with other phenols, are collectively 
known as “mango latex,” which acts as a preservative with 
anti-microbial properties.5 Hershko et al. identified that mango 
pickers with severe rashes had prior exposures to poison ivy 
or poison oak when compared to pickers with mild or no 
rashes working in the same conditions.6 Interestingly, these 
allergens appear to be negligible in the actual fruit of the 
mango, and patients with a history of mango dermatitis may 
still enjoy the fruit if peeled by another person.7  Although the 
pathophysiology of this cross-reaction is not well described, 
understanding this phenomenon is important due to the 
abundance of mango fruits worldwide.
Management of mango dermatitis and contact dermatitis 
from poison ivy or poison oak is nearly identical and primarily 
entails avoidance of inciting factors and symptomatic treatment. 
Post-exposure, patients should be advised to gently rinse the 
affected area with cold, soapy water, ideally within 30 minutes, 
to minimize dermal absorption. Cool compresses and calamine 
lotions are OTC options for symptomatic management.1 Adjunct 
systemic corticosteroids are indicated in moderate to severe 
dermatitis, typically dosed at 1 mg per kilogram per day (kg/day) 
for 14-21 days.1 Although the length of corticosteroid therapy is 
not extensively studied, the prolonged course is recommended 
over shorter courses to prevent rebound dermatitis.8  
Of note, atopic dermatitis (a type I hypersensitivity response) 
and contact dermatitis (a type IV hypersensitivity response) can 
present similarly, and understanding the differences between 
the two can guide treatment, such as the use of antihistamines, 
and identifying inciting factors. This patient was given IV 
antihistamines on arrival, to provide symptomatic relief for a 
presumed, undifferentiated allergic reaction that disrupted the 
patient’s sleep.  Based on our current understanding of pruritus, 
especially in non-histamine mediated pruritus (i.e., contact 
dermatitis), the use of either IV or oral antihistamines has limited 
evidence for use. However, antihistamines can provide a sedating 
effect that may be useful in select patients who are unable to sleep 
secondary to extreme pruritus.9
CONCLUSION
Rashes are common presentations to the ED. While most 
are non-anaphylactic and therefore generally non-emergent, 
key dietary and exposure histories are helpful in determining 
the etiology and treatment of undifferentiated rashes in the 
ED setting. Clinicians should recognize that cross-reactions 
between allergens are frequent and remain suspicious about 
cross-hypersensitivity reactions in any patient with a known 
history of allergic reactions.
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Documented patient informed consent and/or Institutional Review 
Board approval has been obtained and filed for publication of this 
case report.
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